NeoGenomics, Inc. (NEO) |
|
16.87 -1.29 (-7.1%)
|
03-24 16:00 |
|
Open: |
17.75 |
Pre. Close: |
18.16 |
|
High:
|
17.795 |
Low:
|
16.7 |
|
Volume:
|
1,519,768 |
Market Cap:
|
2,150(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:14 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 22.78 One year: 26.61 |
| Support: |
Support1: 15.48 Support2: 13 |
| Resistance: |
Resistance1: 19.51 Resistance2: 22.78 |
| Pivot: |
18.1 |
| Moving Average: |
MA(5): 18.1 MA(20): 17.81 
MA(100): 12.29 MA(250): 10.59 |
| MACD: |
MACD(12,26): 1 Signal(9): 1.2 |
| Stochastic oscillator: |
%K(14,3): 44.2 %D(3): 59.8 |
| RSI: |
RSI(14): 50.4 |
| 52-week: |
High: 19.51 Low: 6 |
| Average Vol(K): |
3-Month: 1,062 (K) 10-Days: 1,229 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NEO ] has closed above bottom band by 5.1%. Bollinger Bands are 24.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
17.82 - 17.91 |
17.91 - 17.98 |
|
Low:
|
16.5 - 16.59 |
16.59 - 16.67 |
|
Close:
|
16.74 - 16.88 |
16.88 - 17 |
|
Company Description |
|
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida. |
Headline News |
Sat, 25 Mar 2023
StockNews.com has downgraded NeoGenomics (NASDAQ:NEO) to ... - Best Stocks
Fri, 24 Mar 2023
NeoGenomics (NASDAQ:NEO) Downgraded to Sell at StockNews.com - MarketBeat
Thu, 23 Mar 2023
NeoGenomics Inc. (NEO) Shares Down Despite Recent Market ... - The News Heater
Wed, 22 Mar 2023
Massive Bio and NeoGenomics Announce Collaboration to ... - Business Wire
Fri, 17 Mar 2023
Lifshitz Law PLLC Announces Investigations of Generac Holdings ... - GlobeNewswire
Mon, 13 Mar 2023
AlphaCrest Capital Management LLC Raises Stake in ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
126 (M) |
| Shares Float |
122 (M) |
|
% Held by Insiders
|
3.3 (%) |
|
% Held by Institutions
|
88.8 (%) |
|
Shares Short
|
4,430 (K) |
|
Shares Short P.Month
|
3,510 (K) |
Stock Financials |
|
EPS
|
0.03 |
|
EPS Est Next Qtl
|
0.03 |
|
EPS Est This Year
|
0.12 |
|
EPS Est Next Year
|
0.23 |
|
Book Value (p.s.)
|
6.19 |
|
Profit Margin (%)
|
-32.9 |
|
Operating Margin (%)
|
-31.7 |
|
Return on Assets (ttm)
|
-5.4 |
|
Return on Equity (ttm)
|
-15.2 |
|
Qtrly Rev. Growth
|
6 |
|
Gross Profit (p.s.)
|
1.52 |
|
Sales Per Share
|
3.93 |
|
EBITDA (p.s.)
|
-0.76 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-82 (M) |
|
Levered Free Cash Flow
|
-104 (M) |
Stock Valuations |
|
PE Ratio
|
421.75 |
|
PEG Ratio
|
-13.4 |
|
Price to Book value
|
2.72 |
|
Price to Sales
|
4.28 |
|
Price to Cash Flow
|
-25.96 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
